About Aeolus Pharmaceuticals (OTCMKTS:AOLS)
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$2.08 million
Price / Sales0.31
Price / CashN/A
Book Value$0.02 per share
Price / Book0.21
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions
What is Aeolus Pharmaceuticals' stock symbol?
Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."
How were Aeolus Pharmaceuticals' earnings last quarter?
Aeolus Pharmaceuticals (OTCMKTS:AOLS) posted its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter. View Aeolus Pharmaceuticals' Earnings History.
When is Aeolus Pharmaceuticals' next earnings date?
Who are some of Aeolus Pharmaceuticals' key competitors?
Who are Aeolus Pharmaceuticals' key executives?
Aeolus Pharmaceuticals' management team includes the folowing people:
- Mr. David C. Cavalier, Chairman, CFO & Sec. (Age 49)
- Mr. John L. McManus, CEO & Pres (Age 54)
- Mr. Christopher Stanley, VP of Operations
- Dr. Brian J. Day Ph.D., Chief Scientific Officer (Age 58)
Has Aeolus Pharmaceuticals been receiving favorable news coverage?
Press coverage about AOLS stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aeolus Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.41 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Aeolus Pharmaceuticals?
Shares of AOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aeolus Pharmaceuticals' stock price today?
One share of AOLS stock can currently be purchased for approximately $0.0042.
How big of a company is Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals has a market capitalization of $790,000.00 and generates $2.08 million in revenue each year. Aeolus Pharmaceuticals employs 4 workers across the globe.
How can I contact Aeolus Pharmaceuticals?
Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]
MarketBeat Community Rating for Aeolus Pharmaceuticals (AOLS)MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe AOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Analyst Ratings History
(Data available from 4/20/2016 forward)
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Earnings History and Estimates Chart
Aeolus Pharmaceuticals (OTCMKTS AOLS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/21/2018|| || || || || || || || |
|8/14/2017||Q3 2017||($0.01)||$0.01 million||View||N/A|
|5/15/2017||Q2 2017||($0.01)||$0.13 million||View||N/A|
|2/17/2017||Q1 2017||($0.01)||$0.08 million||View||N/A|
|12/21/2016||Q4 2016||($0.01)||$0.55 million||View||N/A|
|8/15/2016||Q3 2016||($0.01)||$0.66 million||View||N/A|
|5/16/2016||Q2 2016||($0.02)||$0.57 million||View||N/A|
|2/16/2016||Q1 2016||($0.01)||$0.31 million||View||N/A|
|8/17/2015||Q3 2015||($0.01)||$0.06 million||View||N/A|
|5/15/2015||Q2 2015||($0.01)||$1.19 million||View||N/A|
|2/13/2015||Q1 2015||($0.01)||$0.93 million||View||N/A|
|8/15/2014||Q3 2014||$0.01||$4.98 million||View||N/A|
|2/14/2014||Q1 2014||($0.01)||$0.79 million||View||N/A|
|8/14/2013||Q3 2013||($0.01)||$0.84 million||View||N/A|
|5/15/2013||Q2 2013||($0.01)||$0.86 million||View||N/A|
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 66.60%
Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/6/2013||John L Mcmanus||CEO||Buy||10,000||$0.35||$3,500.00|| |
Aeolus Pharmaceuticals (OTCMKTS AOLS) News Headlines
Aeolus Pharmaceuticals (OTCMKTS:AOLS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Aeolus Pharmaceuticals (OTCMKTS:AOLS) Income Statement, Balance Sheet and Cash Flow Statement
Aeolus Pharmaceuticals (OTCMKTS AOLS) Stock Chart for Friday, April, 20, 2018